Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Two-part Randomized, Double Blind, Placebo-controlled Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Emraclidine in Participants With Schizophrenia

NCT07145918 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT07145918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07145918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Two-part Randomized, Double Blind, Placebo-controlled Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Emraclidine in Participants With Schizophrenia
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Recruiting
Start date
August 4, 2025
Completion date
February 29, 2028
Enrollment
268 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia